Pharma & Biotech Mergers & Acquisitions News
Pharmaceutical
Full mergers and acquisitions in the pharmaceutical and biotechnology in 2024 fluctuated throughout the year with hardly any in some months and a significant number in other. But one thing was clear – buyers were shying away from big bets on commercially ready medicines in favor of earlier stage drug developers. 3 January 2025
Today's issue
Refine Search
Latest Mergers & Acquisitions News & Features
Pharmaceutical
In a short time much can change in Japan. A striking example is the move by Japanese pharmaceutical companies to acquire assets outside Japan. Not too long ago Western observers considered local companies as very provincial, protected and strong in Japan but non-competitors in the rest of the world. Today, four Japanese firms realize over 50% of their revenue outside Japan. 10 November 2011
Pharmaceutical
With the aim of improving its innovate products franchise, US drugmaker Salix Pharmaceuticals (Nasdaq: SLXP) has entered into an agreement to acquire privately-held Oceana Therapeutics, a global provider of gastroenterology and urology therapeutics, for $300 million in cash. The transaction is subject to customary conditions to closing, including US anti-trust approval, and is expected to close in December 2011. 9 November 2011
Pharmaceutical
The planned $21.3 billion acquisition of orthopedic device maker Synthes (SYST: VX), which is listed in Switzerland but operates out of the USA, by US health care giant Johnson & Johnson (NYSE: JNJ) is likely to face antitrust delays in Europe (The Pharma Letter April 27), as the European Commission announced last Friday that it has opened an in-depth investigation under the European Union Merger Regulation into the deal. 6 November 2011
Pharmaceutical
French drugmaker Ipsen (Euronext: IPN) today has sold its North American development and marketing rights for Apokyn (apomorphine) indicated in the USA for the acute, intermittent treatment of hypomobility 'off' episodes associated with advanced Parkinson's disease to UK-based Britannia Pharmaceuticals, now part of Germany's STADA Arzneimittel. 3 November 2011
Pharmaceutical
USA-based SurModics (Nasdaq: SRDX), a provider of surface modification technologies to the healthcare industry, has entered into a definitive agreement to sell its SurModics Pharmaceuticals assets to privately-held German specialty chemicals group Evonik Industries for $30 million in cash. 2 November 2011
Pharmaceutical
French drug major Sanofi (Euronext: SAN) is expected to take the top spot amongst the world's pharmaceuticals manufacturers in 2012 and hold it through 2016, according to a new report by life sciences analyst EvaluatePharma. 1 November 2011
Pharmaceutical
ViroPharma to acquire DuoCort Pharma for up to $164 million, adding European orphan drug to pipeline
The USA's ViroPharma (Nasdaq: VPHM) says it has signed a definitive agreement to acquire DuoCort Pharma AB, a private company based in Helsingborg, Sweden, focused on improving glucocorticoid replacement therapy. The acquisition of DuoCort will further expand ViroPharma's orphan disease commercial product pipeline. 28 October 2011
Pharmaceutical
USA-based Repligen (Nasdaq: RGEN) says it has signed a definitive agreement to acquire the business of Novozymes Biopharma Sweden AB from Denmark-based parent Novozymes (Nasdaq: NZYM B) in a cash transaction of 17 million euros ($22.7 million) and future potential milestone payments of 4 million euros ($5.6 million). 28 October 2011
Pharmaceutical
California, USA-based Arrowhead Research Corp Nasdaq: ARWR) said yesterday that it has acquired RNA therapeutics assets from Swiss drug major Roche (ROG: SIX) including the state-of-the-art research site in Madison, Wisconsin. As part of the deal, financial terms of which were not disclosed, Roche has obtained a minority stake in Arrowhead as well as rights to negotiate for certain future products, milestone payments and royalties on sales. 25 October 2011
Pharmaceutical
Switzerland-based Ferring Pharmaceuticals says that it has completed the purchase of USA-based Cytokine PharmaSciences (CPSI) and its UK subsidiary Controlled Therapeutics (Scotland; CTS), a global biopharmaceutical company with a particular focus in obstetrics. Financial terms of the deal were not disclosed. 25 October 2011
Pharmaceutical
Privately-held Irish drugmaker Immdal last week announced the sale of its subsidiary Newport Pharmaceuticals to also privately-owned Swiss pharmaceutical company Ewopharma AG. Financial terms of the transaction were not revealed. 24 October 2011
Pharmaceutical
In a further move to broaden in presence outside its current domination in the oncology sector, Swiss drug major Roche (ROG: SIX) said yesterday that it has signed a definitive merger agreement to fully acquire California based Anadys Pharmaceuticals (Nasdaq: ANDS) for $230 million, or $3.70 per share, in cash. The offer price represents a 256% premium to the closing price on October 14, 2011. 18 October 2011
Pharmaceutical
Following US antitrust clearance last week, Israel-based Teva Pharmaceutical Industries (Nasdaq: TEVA) has received approval from the European Commission to proceed with its $6.8 billion acquisition of US biotech firm Cephalon (Nasdaq: CEPH), but again with conditions (The Pharma Letter October 10). 14 October 2011
Pharmaceutical
Japanese drugmaker Santen Pharmaceuticals (TYO: 4536) says it has completed its previously-announced acquisition of 50.55% of French ophthalmology pharmaceuticals company Novagali Pharma (NYSE Euronext Paris: NOVA) for 6.15 euros per share, in a deal that values the entire company at around 100 million euros ($134.9 million). 13 October 2011
Pharmaceutical
Allos Therapeutics (Nasdaq: ALTH) says that it continues to work with fellow USA-based AMAG Pharmaceuticals (Nasdaq: AMAG) toward completing their previously-announced $686 million stock merger (The Pharma Letter July 21), pending stockholder approval and satisfaction of the other conditions to closing described in Allos' definitive proxy statement filed with the Security and Exchange Commission on September 15. 11 October 2011
Pharmaceutical
USA-based Biostar Pharmaceuticals (Nasdaq GM: BSPM) announced that its wholly owned subsidiary, Shaanxi Aoxing Pharmaceutical, has entered into a share transfer agreement to acquire Shaanxi Weinan Huaren Pharmaceuticals. The aggregate purchase price is RMB 61 million renminbi (around $9.62million), all cash and payable in several tranches. 11 October 2011
Pharmaceutical
German pharma services provider Celesio (CLS1.XE), which recently issued a profit warning due to the intensity of competition in Germany's pharmaceutical wholesale business, says it has acquired a 60% stake in the Brazilian Oncoprod Group, which is the leading wholesaler for specialty pharmaceuticals in Brazil. Financial terms of the deal were not disclosed. 11 October 2011
Pharmaceutical
In recent years consolidation on the Russian pharmaceutical distribution market has taken place mostly in the retail, whereas there has been stagnation on the wholesale market. In Ukraine acquisitions in both wholesale and retail pharmaceutical distribution stopped because of the more cautious policies of companies during the crisis, according to the latest report from Poland-based market research firm PMR, titled Distribution on the pharmaceutical market in Russia and Ukraine 2011. 6 October 2011
Pharmaceutical
The Indian subsidiaries of US drug major Eli Lilly (NYSE: LLY) and independent German pharma company Boehringer Ingelheim are entering an India-specific agreement to co-promote a portfolio of diabetes compounds currently either in late-stage development or on the market. The collaboration includes Lilly's insulin analogue, Humalog (insulin lispro), which is already on the Indian market, and Boehringer Ingelheim's oral anti-diabetic agent, linagliptin (trade named Trajenta in Europe and Tradjenta in the USA), not yet approved for marketing in India. 4 October 2011
Pharmaceutical
With the completion of all regulatory and competition authority investigations, Japan's largest drugmaker Takeda Pharmaceutical (TYO: 4502) says it has now finalized its acquisition of independent Swiss pharma company Nycomed for 9.6 billion euros ($12.98 billion) - first announced in the spring (The Pharma Letter May 19) - on a cash-free, debt-free basis and made Nycomed a wholly owned subsidiary of Takeda effective the same day. 2 October 2011
Pharmaceutical
Immedica Pharma, a Swedish company specializing in rare diseases, has announced its acquisition of Marinus Pharmaceuticals in a deal valued at $151 million. The agreement, finalized through a cash tender offer, marks a significant expansion of Immedica’s presence in the US market. 6 January 2025
Pharmaceutical
Full mergers and acquisitions in the pharmaceutical and biotechnology in 2024 fluctuated throughout the year with hardly any in some months and a significant number in other. But one thing was clear – buyers were shying away from big bets on commercially ready medicines in favor of earlier stage drug developers. 3 January 2025
Pharmaceutical
Regeneron Pharmaceuticals has acquired UK-based biotech Oxular, enhancing its gene therapy development program with the firm’s specialized ocular delivery tech. 3 January 2025
Pharmaceutical
Denmark-based diabetes and obesity giant Novo Nordisk says it plans to invest 8.5 billion Danish kroner ($1.2 billion) to establish a completely new production facility in Odense, Denmark. 16 December 2024
Pharmaceutical
The pharmaceutical and life sciences industry is gearing up for what analysts at PwC predict will be a highly active year for mergers and acquisitions in 2025, following a mixed performance in 2024. 13 December 2024
Pharmaceutical
Canada-headquartered Bausch + Lomb Corporation, a leading global eye health company, on Thursday confirmed reports that it is exploring a potential sale, acting in response to a request from the Canadian Investment Regulatory Organization (CIRO). 13 December 2024
Pharmaceutical
UK-based Tenpoint Therapeutics and Seattle’s Visus Therapeutics have announced the completion of their merger to create an entirely new chapter in ophthalmic therapeutic medicines aimed at rejuvenating the aging eye. 12 December 2024
Pharmaceutical
The European Commission has approved unconditionally, under the EU Merger Regulation, the proposed acquisition of contract development and manufacture organization (CDMO) Catalent (NYSE: MCTLT) by Denmark’s Novo Holdings. 7 December 2024
Pharmaceutical
GE Healthcare has announced plans to acquire from Sumitomo Chemical the half of Nihon Medi-Physics (NMP) that it doesn’t own. 5 December 2024
Pharmaceutical
Germany’s Evotec has said its chief operating officer Craig Johnstone will leave the business at the end of the year. 29 November 2024
Pharmaceutical
Munich, Germany headquartered contract development and manufacturing organization (CDMO) Adragos Pharma has acquired Baccinex, a Swiss-based expert in aseptic fill-finish manufacturing. 28 November 2024
Pharmaceutical
The board of Spanish plasma-based medicines producer Grifols has announced the termination of discussions with Brookfield Capital Partners (UK) regarding a potential acquisition of Grifols shares. 28 November 2024
Pharmaceutical
Swiss pharma giant Novartis today announced an upgrade to its mid-term guidance, in advance of its Meet Novartis Management event for investors and analysts in London. 21 November 2024
Pharmaceutical
Big pharmas are not deterred by China’s increasingly complex business environment. Instead, they are changing strategies to minimize risks while continuing to benefit from China, said speakers at ChinaTrials held last week in Shanghai. 18 November 2024
Pharmaceutical
Life science investor Syncona has announced the launch of its newest portfolio company, Slingshot Therapeutics, through the Syncona Accelerator initiative. 14 November 2024
Pharmaceutical
European regulators will decide by December 6 whether Novo Holdings, the controlling shareholder of Danish pharma giant Novo Nordisk, can finalize its $16.5 billion acquisition of contract drug manufacturer Catalent. 5 November 2024
Pharmaceutical
Pharmaceutical M&A came back with a bang during October, after a quiet September. 5 November 2024
Pharmaceutical
US pharma major AbbVie last week proposed $1.4 billion acquisition of US CNS drug developer Aliada Therapeutics. Last week saw a bunch of third quarter 2024 financials results, among which were Elil Lilly, AbbVie and Merck & Co. Also of note, Lexicon’s type I diabetes drug Zynquista faced a Food and Drug Administration (FDA) advisory committee review that resulted in largely negative vote against recommendation. 3 November 2024
Pharmaceutical
Melbourne, Australia-based Telix Pharmaceuticals has announced the launch of Rhine Pharma, a subsidiary aimed at increasing global access to radiopharmaceuticals for cancer treatment and imaging. 22 October 2024
Pharmaceutical
French pharma major Sanofi has opened negotiations to sell a 50% controlling stake in its consumer health business Opella to US private equity firm Clayton Dubilier & Rice (CD&R). 21 October 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze